# MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB

> **NCT02643654** · PHASE2 · COMPLETED · sponsor: **Evangelos J. Giamarellos-Bourboulis, M.D.** · enrollment: 20 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** MABp1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02643654
- **Lead sponsor:** Evangelos J. Giamarellos-Bourboulis, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-10
- **Final completion:** 2017-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02643654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02643654, "MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02643654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*